Multithread effectively and personalize outreach to convert deals faster
Elevate social presence and drive business growth from social media
Identify and prioritize high-intent leads, and improve sales effectiveness
Find and connect with ICP attendees, and improve event outcomes
Evolus (NASDAQ: EOLS) is a performance beauty company with a customer-centric approach focused on delivering impactful innovation. The company's lead product is Jeuveau® (prabotulinumtoxinA-xvfs), a proprietary 900 kilodalton (kDa) purified botulinum toxin type A neurotoxin approved for the temporary improvement in the appearance of moderate to severe glabellar lines in adults. Evolus is focused on building a portfolio of differentiated products in aesthetics, with a current emphasis on expanding the market for Jeuveau® and developing its 'extra-strength' Nuceiva® (the brand name for Jeuveau in Europe and Canada) and its EvolFlex™ 'smart toxin' platform.
Serves as the central hub for corporate strategy, research and development, marketing, financial operations, and overall global management of Evolus's medical aesthetics business.
Modern office facilities located in Newport Center, a prominent business district known for Class A office spaces, likely featuring collaborative workspaces and technology to support a dynamic workforce.
Characterized by innovation, a fast-paced environment driven by the 'performance beauty' ethos, collaboration across departments, and a strong focus on scientific advancement and customer (healthcare provider and consumer) satisfaction.
Key decision-making center for a publicly traded company (NASDAQ: EOLS) competing in the rapidly growing global medical aesthetics market, particularly for its flagship neurotoxin product, Jeuveau®.
Evolus supports functions globally including sales, marketing, medical affairs, regulatory compliance, and distribution partnerships. Key markets include the United States (with Jeuveau®) and an expanding presence in international markets such as Canada, Great Britain, Germany, Austria, and Italy with Nuceiva®. The company is actively pursuing further geographic expansion.
520 Newport Center Drive, Suite 1200
Newport Beach
CA
USA
Address: Uncommon, 1 Long Lane, London, SE1 4PG, United Kingdom (for Evolus Limited)
To establish and grow Evolus's footprint in the European aesthetics market, manage commercialization of Nuceiva®, and engage with healthcare professionals and partners in the region.
Address: Registered address for Evolus International Limited (specific office details may vary)
Supports the expansion and operational management of Evolus's business across Europe and other international territories.
Highperformr Signals uncover buying intent and give you clear insights to target the right accounts at the right time — helping your sales, marketing, and GTM teams close more deals, faster.
As of April 2025, Evolus' leadership includes:
Evolus has been backed by several prominent investors over the years, including:
In the past 12 months, Evolus has strengthened its commercial leadership with a key new hire for its U.S. operations. No major C-suite departures have been publicly announced during this period for the current executive team.
Discover the tools Evolus uses. Highperformr reveals the technologies powering your target accounts — helping your sales, marketing, and GTM teams prioritize smarter and close faster.
Evolus primarily uses the '[first_initial][last]@evolus.com' email format for its employees. This is a common pattern observed for the company.
[first_initial][last]@evolus.com
Format
jdoe@evolus.com
Example
85%
Success rate
Evolus, Inc. / Business Wire • May 7, 2024
Evolus announced record Q1 net revenue of $59.3 million, a 41% increase year-over-year, driven by strong Jeuveau® sales and customer growth. The company reiterated its 2024 net revenue guidance and highlighted progress in international expansion and its EvolFlex™ 'smart toxin' development program....more
Evolus, Inc. / Business Wire • February 1, 2024
Evolus announced the appointment of Michael Jafar as Chief Commercial Officer, Jeuveau® U.S., effective February 5, 2024. Jafar brings over two decades of experience in aesthetics, consumer brands, and commercial leadership to drive the U.S. growth strategy for Jeuveau®....more
Evolus, Inc. / Business Wire • April 2, 2024
Evolus announced the commercial launch of Nuceiva® (prabotulinumtoxinA-xvfs) in Italy, marking its fourth major European country launch. This expansion is part of Evolus's strategy to grow its international presence in the medical aesthetics market....more
See where a company’s workforce is located, by country or region.
View past and recent funding rounds with amounts and investors.
Understand company revenue estimates and financial scale.
Track active roles and hiring trends to spot growth signals.
Discover what a company offers—products, platforms, and solutions.
Get the company’s official SIC and NAICS classifications.
Analyze visitor volume, engagement, and top traffic sources.
Explore LinkedIn, Twitter, and other active social profiles.
Identify top competitors based on similar business traits.
Explore companies in depth — from the tech they use to recent funding, hiring trends, and buyer signals — all in one powerful view.
Highperformr AI helps you surface the right accounts and enrich your CRM with verified company and contact insights, so your teams can prioritize and engage faster.
Thousands of companies, including Evolus, are just a search away.